How would you, the CEO, respond to criticisms of being “profit-driven” by a leading director of the World Health Organization (WHO) if contacted by the press during the Ebola crisis
In Closing Case: The Ebola Challenge, pages 245-246, Dr. Margaret Chan expresses concerns and frustrations regarding the profit-driven motivations of the pharmaceutical industry, implying that they have a partial responsibility for the Ebola Crisis that the world was facing at the time. After reading the Closing Case, consider the dilemmas presented from the perspective of a CEO of a small, but profitable pharmaceutical firm, and answer the following questions:
Do you personally think that pharmaceutical companies have an ethical obligation to include potentially non-profitable products as part of a Corporate Social Responsibility (CSR) commitment or strategy? Does that change when you are in the position of leading a profitable firm?
How would you, the CEO, respond to criticisms of being “profit-driven” by a leading director of the World Health Organization (WHO) if contacted by the press during the Ebola crisis?
Suppose you and your board determine it is feasible to create a CSR strategy for your company, what are some of the resource- and institution-based considerations you would explore?
What kind of CSR strategy would you pursue, knowing more global health crises like the Ebola outbreak and COVID-19 global pandemic will emerge?
Be sure to use insights from this week’s reading in your answers. In your paper, use your textbook and at least two peer-reviewed sources along with their citations and references. Your paper must be APA formatted and include at least 1500 words.